Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-06-08
1998-09-01
Achutamurthy, Ponnathapura
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514262, 544265, 544276, A01N 4342, A01N 4390, C07D47300
Patent
active
058011846
ABSTRACT:
Disclosed herein are methods directed generally to the control of neural activity and for selectively and controllably inducing the in vivo genetic expression of one or more naturally occurring genetically encoded molecules in mammals. More particularly, the present invention selectively activates or derepresses genes encoding for specific naturally occurring molecules such as neurotrophic factors through the administration of carbon monoxide dependent guanylyl cyclase modulating purine derivatives. The methods of the present invention may be used to affect a variety of cellular and neurological activities and to therapeutically or prophylactically treat a wide variety of neurodegenerative, neurological, and cellular disorders.
REFERENCES:
patent: 3321369 (1967-05-01), Glasky et al.
patent: 3438968 (1969-04-01), Glasky
patent: 4035486 (1977-07-01), Laborit
patent: 4221910 (1980-09-01), Sorolla
patent: 4952693 (1990-08-01), Sircan et al.
patent: 5091432 (1992-02-01), Glasky
patent: 5256677 (1993-10-01), Sham et al.
Sylvain Lehmann et al., "Neurite outgrowth of neurons . . . guanidine group", Neuroscience Letters, 1993, 152:57-60, Elsevier Sci. Pub. Ireland Ltd.
Marcia Barinaga, "Carbon Monoxide: Killer to Brain Messenger in One Step", Science, 15 Jan. 1993, 259:309.
Ajay Verma et al., "Carbon Monoxide: A Putative Neural Messenger", Science, 15 Jan. 1993, 259:381-384.
Min Zhuo et al., "Nitric Oxide and Carbon Monoxide . . . Hippocampus", Science 25 Jun. 1993, 260:1946-1950.
.ANG.Ake Seiger et al., "Intracranial infusion of purified nerve . . . strategy" Behavioral Brain Research, 1993, 57:255-261.
Atsumi Nitta et al., "Effects of oral administration . . . in basal fore-brain lesioned rats", Eur. Journal of Pharmacology, 1993, 250:23-30.
M.H. Tuszynski & F.H. Gage, "Neurotrophic Factors and Neuronal Loss", Ch.25, Alzheimer Disease, R.D. Terry et al., eds., 1994, 405-417, Raven Press, NY.
R.D. Hawkins et al., "Nitric Oxide and Carbon monoxide . . . Lont-Term Potentiation," Journal of Neurobiology, 1994, 25:6, pp. 652-665.
S.H. Snyder, "NO and CO: The Body's Unprecedented Signaling Molecules," 1995 Yearbook of Sci. & The Future, Encyc.Brit., pp. 96-99.
Copy of the abstract from an article by E. G. Jung (Therampiewoch, vol. 34, No. 17, pp. 2615-2618, 1984) entitled "Chemotherapie Multiplier Warzen Mit Inosiplex".
Glasky Alvin J.
Rathbone Michel P.
Achutamurthy Ponnathapura
Park Hankyel T.
LandOfFree
Carbon monoxide dependent guanylyl cyclase modifiers and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carbon monoxide dependent guanylyl cyclase modifiers and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carbon monoxide dependent guanylyl cyclase modifiers and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-270606